https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=14600
No pharmaceutical opinion available for this interaction.
Elvitegravir / Cobicistat can induce the metabolism (CYP 2C9) and decrease the plasma concentration of Glicazide.
–
–
–
Possible decrease of clinical efficacy.
Monitor for clinical efficacy and adjust the dosage if necessary.
Metformin, DPP-4 Inhibitors, GLP-1 Agonists
–
Blood Sugar
–
Ref #3187 : Co-administration of 600 mg rifampicin, a potent CYP2C9 inducer, and a single dose of glicazide 80 mg (after 7 days of once daily rifampicin 600 mg) resulted in a 70% in glicazide AUC.